Many AMD patients are legally blind. Do you really want them fooling around with a syringe? Moreover, subcutaneous dosing tends to be less precise than IV dosing, so the FDA would be apt to be more cautious about systemic safety in a sub-Q formulation.
In short, I don’t see the sub-Q route being an important one for drugs in this indication.
Market Data 
Markets 
AI
